These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20601821)

  • 41. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle.
    Malhotra P; Palanisamy R; Falasca M
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):4-6. PubMed ID: 34535394
    [No Abstract]   [Full Text] [Related]  

  • 42. The case for a stratified application of targeted agents against pancreatic cancer.
    Bijlsma MF
    EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122
    [No Abstract]   [Full Text] [Related]  

  • 43. Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Kuang Y; Sechi M; Nurra S; Ljungman M; Neamati N
    J Med Chem; 2018 Feb; 61(4):1576-1594. PubMed ID: 29328656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    Gromisch C; Qadan M; Machado MA; Liu K; Colson Y; Grinstaff MW
    Cancer Res; 2020 Aug; 80(16):3179-3192. PubMed ID: 32220831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Necrotizing pancreatitis caused by pancreatic ductal adenocarcinoma.
    Zyromski NJ; Haidenberg J; Sarr MG
    Pancreas; 2001 May; 22(4):431-2. PubMed ID: 11345146
    [No Abstract]   [Full Text] [Related]  

  • 46. Conceptual framework for cutting the pancreatic cancer fuel supply.
    Le A; Rajeshkumar NV; Maitra A; Dang CV
    Clin Cancer Res; 2012 Aug; 18(16):4285-90. PubMed ID: 22896695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonviral siRNA delivery systems for pancreatic cancer therapy.
    Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
    Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic Potential for FGFR Inhibitors in SOX9-FGFR2 Coexpressing Pancreatic Cancer.
    OʼSullivan H; Kelleher FC; Lavelle M; McGovern B; Murphy J; Swan N; McDermott R
    Pancreas; 2017 Sep; 46(8):e67-e69. PubMed ID: 28796141
    [No Abstract]   [Full Text] [Related]  

  • 49. Erythropoietin-producing pancreatic ductal adenocarcinoma.
    Kawai H; Kojima M; Yokota M; Iguchi H; Wakasugi H; Jimi A; Funakoshi A
    Pancreas; 2000 Nov; 21(4):427-9. PubMed ID: 11075999
    [No Abstract]   [Full Text] [Related]  

  • 50. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.
    Chan E; Berlin J
    J Clin Oncol; 2014 Feb; 32(6):487-8. PubMed ID: 24419124
    [No Abstract]   [Full Text] [Related]  

  • 51. Pancreatic cancer: New insights into PDAC growth promotion via a BAG3-mediated paracrine loop.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):669. PubMed ID: 26577348
    [No Abstract]   [Full Text] [Related]  

  • 52. NF-kappa B--a target in the inflammation of bone destruction.
    Doggrell SA
    Expert Opin Ther Targets; 2005 Feb; 9(1):191-3. PubMed ID: 15757490
    [No Abstract]   [Full Text] [Related]  

  • 53. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response.
    Walsh AJ; Castellanos JA; Nagathihalli NS; Merchant NB; Skala MC
    Pancreas; 2016 Jul; 45(6):863-9. PubMed ID: 26495796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer.
    Gunturu KS; Abu-Khalaf M; Saif MW
    JOP; 2010 Sep; 11(5):484-5. PubMed ID: 20818124
    [No Abstract]   [Full Text] [Related]  

  • 55. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.
    Liu X; Jiang J; Meng H
    Theranostics; 2019; 9(26):8018-8025. PubMed ID: 31754378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress.
    Kang M; Qin W; Buya M; Dong X; Zheng W; Lu W; Chen J; Guo Q; Wu Y
    Cancer Lett; 2016 Apr; 373(2):241-50. PubMed ID: 26845448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of inflammation in cancer and systemic lupus erythematosus.
    Rinaldi I
    Acta Med Indones; 2013 Jul; 45(3):167-9. PubMed ID: 24045384
    [No Abstract]   [Full Text] [Related]  

  • 58. Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology.
    Zygmunt A; Gubernator J
    Expert Opin Drug Deliv; 2024 Jun; 21(6):845-865. PubMed ID: 38899424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel targets in pancreatic cancer: focus on future paths to therapy.
    Cohen SJ; Burtness BA
    Expert Opin Ther Targets; 2006 Oct; 10(5):771-5. PubMed ID: 16981833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pancreatic carcinoma complicating tropical pancreatitis in north India.
    Das K; Goenka MK; Wig JD; Nagi B; Bhasin D
    Indian J Gastroenterol; 1996 Jul; 15(3):103. PubMed ID: 8840639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.